Indian pharmaceutical company Glenmark Pharmaceuticals will manufacture the spray in India and intends to produce, market and distribute it to other Asian countries, including Singapore, Malaysia, and Taiwan, the announcement from SaNotize said. Some, countries, including Israel, have already made the spray available as a medical device.
In August, SaNOtize inked an agreement with the pharmaceutical company, established in 1977 and headquartered in the country’s commercial capital, Mumbai, to manufacture the spray
The spray is deemed effective at reducing viral load with mild cases of COVID-19 and received successful results in Phase 3 clinical trials.
In a randomized double blind trial involving 306 participants, those who received a dose from the spray were found to be free of the virus within four days usually and they were found to be less likely to pass infections onto others. It took those who received a placebo twice as long to clear the virus from their systems, and in both cases, zero safety issues occurred.
“These results definitively substantiate the safety and efficacy of NONS in the fight against COVID-19,” said Dr. Gilly Regev, SaNOtize co-founder and CEO. “We are thrilled to be able to provide COVID patients with an affordable product that has been shown to deliver a faster cure. And with the proven safety profile of NONS, we look forward to this becoming the first line of treatment and potentially defense for COVID infection worldwide.”